ArticleVeterinary medicine and science2025
Comparative Clinico-Haematological Alterations of Lumpy Skin Disease Affected Cattle at Different Ages and Periods of Disease in Bangladesh.
Article in Veterinary medicine and science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Clinico-Haematological Alterations of Lumpy Skin Disease Affected Cattle at Different Ages and Periods of Disease in Bangladesh.Veterinary medicine and science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesLumpy skin disease (LSD) is a transboundary viral pox disease that causes huge economic losses. The disease is in an epidemic situation, and the affected cattle show massive lesions and complexity, which is tough to treat; thus, a study was conducted to investigate the clinico-haematological alterations of LSD-affected cattle for adopting better pharmacotherapeutic management. MATERIAL AND
methodsA total of 36 LSD affected, and 8 healthy/control cattle were examined and used for blood profiling. The control and affected cattle were categorized into four age groups consisting of nine cattle (Group A = under 1 year; Group B = 1 to 2 years; Group C = 2 to 3 years; and Group D = from 4 years up to 10 years) in each group and three disease periods of post infection (prodromal period, period of illness and period of decline) consist of each of 12 LSD affected cattle.
resultsClinical examination of affected cattle showed 100% cattle (skin nodule of various sizes), 55.55% (lymph node enlargement), 75% (high fever), 13.88% (brisket oedema), 19.44% (limb oedema), 8.33% (ventral abdomen oedema), 5.55% (facial oedema), 19.44% (lameness), 22.22% (respiratory distress), 2.77% (corneal opacity) and 27.78% (salivation and nasal discharge) as clinical signs. Almost all affected cattle showed multiple lesion at the same time, particularly in the last two disease periods. Comparatively, the nodular lesion is much more higher in the limb (33.1%), followed by the head and neck region (23.24%), and then other parts of the body. Haematological analysis reveals a significant decrease in red blood cell (RBC), haemoglobin (Hb), packed cell volume (PCV), mean corpuscular Hb concentration (MCHC), TLC and thrombocytes. During the illness and decline periods, mean corpuscular volume (MCV) increased, which is an indication of macrocytic hypochromic anaemia, lymphocytopenia and thrombocytopenia, and indicative of fluid therapy such as blood transfusion. The age group under 1 year is more vulnerable to LSD fatality, as lower levels of TLC, lymphocyte, and monocyte were found, indicating severe immunosuppression.
conclusionIt is concluded that disease stage-wise and age-wise clinico-haematological studies have provided baseline data of LSD pathogenesis, which is essential to formulate an effective pharmacotherapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.